Irinotel Injection contains Irinotecan, a chemotherapeutic agent supplied as 100mg per 5ml solution for intravenous administration. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. It is primarily indicated for the treatment of metastatic colorectal cancer, either as a single agent or in combination with other chemotherapeutic drugs such as fluorouracil and leucovorin. The drug is administered under strict medical supervision, with dosing tailored according to patient body surface area, treatment response, and tolerability. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and fatigue, necessitating close monitoring of blood counts and supportive care measures. Irinotel Injection should be used cautiously in patients with hepatic impairment or pre-existing gastrointestinal disorders. Due to its potential for severe toxicity, dose adjustments may be required based on hematologic and non-hematologic toxicities. It is contraindicated in patients with known hypersensitivity to Irinotecan or its components. Proper preparation and handling procedures must be followed to minimize exposure risks to healthcare personnel. Irinotel Injection represents a critical option in the management of advanced colorectal malignancies, contributing to improved patient outcomes when integrated into comprehensive oncologic treatment regimens.